KRAS and cancer: Oncogene KRAS activation by endogenous mutations or exogenous expression in luminal epithelial breast cells also promotes development of neoplastic lesions that evolve to claudin-low or basal-like cancers with triple-negative phenotypes, in a mouse model [40].